330 related articles for article (PubMed ID: 12096353)
1. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
Pearson TC
Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
3. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
5. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
8. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
9. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC; Gómez M
Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
[TBL] [Abstract][Full Text] [Related]
10. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
11. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.
Lakhwani S; Pardina-Echevarría M; Arcas-Vega R; Díaz-Sánchez OR; Hernández-García MT; Raya JM
Rev Clin Esp (Barc); 2022 Mar; 222(3):169-173. PubMed ID: 34657827
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia vera and essential thrombocythemia in young patients.
Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
[TBL] [Abstract][Full Text] [Related]
13. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
14. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
15. Polycythaemia vera and essential thrombocythaemia in the elderly.
van Genderen PJ; Troost MM
Drugs Aging; 2000 Aug; 17(2):107-19. PubMed ID: 10984199
[TBL] [Abstract][Full Text] [Related]
16. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
17. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Michiels JJ
Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
[TBL] [Abstract][Full Text] [Related]
18. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
19. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Michiels JJ; Berneman Z; Schroyens W; van Urk H
Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947
[TBL] [Abstract][Full Text] [Related]
20. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Michiels JJ; van Genderen PJ; Lindemans J; van Vliet HH
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():47-56. PubMed ID: 8951772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
